نتائج البحث - "Tony W. Ho"

المصدر: Lheureux, S, Lai, Z, Dougherty, B A, Runswick, S, Hodgson, D, Timms, K M, Lanchbury, J S, Kaye, S B, Gourley, C, Bowtell, D D L, Kohn, E C, Scott, C L, Matulonis, U A, Panzarella, T, Karakasis, K, Burnier, J V, Gilks, B, O'connor, M J, Robertson, J D, Ledermann, J, Barrett, J C, Ho, T W & Oza, A M 2017, ' Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization ', Clinical Cancer Research, vol. 23, no. 15, pp. clincanres.2615.2016 . https://doi.org/10.1158/1078-0432.CCR-16-2615Test

مصطلحات موضوعية: Adult, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, DNA repair, medicine.medical_treatment, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Bioinformatics, Placebo, Disease-Free Survival, Piperazines, law.invention, Olaparib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Maintenance therapy, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, BRCA2 Protein, Ovarian Neoplasms, Chemotherapy, BRCA1 Protein, business.industry, Cancer, Middle Aged, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Mutation, Phthalazines, Female, Neoplasm Grading, Neoplasm Recurrence, Local, Tumor Suppressor Protein p53, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ebb617095ff01ea1c8bb88afab437dTest
https://doi.org/10.1158/1078-0432.ccr-16-2615Test

8

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

المصدر: Blood. 136:3-4

مصطلحات موضوعية: business.industry, Thalassemia, education, Immunology, Cell, CD34, Cell Biology, Hematology, medicine.disease, Biochemistry, Haematopoiesis, medicine.anatomical_structure, Medicine, Climb, CRISPR, In patient, Progenitor cell, business, health care economics and organizations

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::51825e58e3d346f75b0a6ca5dd93bca1Test
https://doi.org/10.1182/blood-2020-139575Test

9

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

المؤلفون: Dana Adriana Botesteanu, Elizabeth D. Thompson, Maria I. Harrell, Tony W. Ho, Cody J. Peer, Aleksandra Ogurtsova, Haiying Xu, Janis M. Taube, Ashley Cimino-Mathews, Jung-Min Lee, Christina M. Annunziata, Alexandra Zimmer, Elizabeth M. Swisher, Stanley Lipkowitz, William D. Figg, Jeffers Nguyen, Liang Cao, Nicole D. Houston, Elise C. Kohn

المصدر: Journal of Clinical Oncology. 35:2193-2202

مصطلحات موضوعية: Adult, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Durvalumab, Combination therapy, Genital Neoplasms, Female, Poly(ADP-ribose) Polymerase Inhibitors, Pharmacology, Gastroenterology, B7-H1 Antigen, Piperazines, Olaparib, Cediranib, 03 medical and health sciences, chemistry.chemical_compound, Lymphocytes, Tumor-Infiltrating, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Protein Kinase Inhibitors, Aged, Vascular Endothelial Growth Factor Receptor-1, Dose-Response Relationship, Drug, business.industry, Area under the curve, Antibodies, Monoclonal, ORIGINAL REPORTS, Middle Aged, Dose–response relationship, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Toxicity, Quinazolines, Phthalazines, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e881cebef7d9615b87f95069c85fdf6Test
https://doi.org/10.1200/jco.2016.72.1340Test

10

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

المؤلفون: Jane Robertson, Anitra Fielding, Zhongwu Lai, Mark J. O'Connor, Kirsten Timms, Tony W. Ho, Jonathan A. Ledermann, Maria Orr, Stuart Spencer, J. Carl Barrett, Helen Jones, Darren Hodgson, Chris Womack, Jerry S. Lanchbury, Alexander Gutin, Lynda Grinsted, Brian Dougherty, Charlie Gourley, Blake Gilks

المصدر: Hodgson, D R, Dougherty, B A, Lai, Z, Fielding, A, Grinsted, L, Spencer, S, O’connor, M J, Ho, T W, Robertson, J D, Lanchbury, J S, Timms, K M, Gutin, A, Orr, M, Jones, H, Gilks, B, Womack, C, Gourley, C, Ledermann, J & Barrett, J C 2018, ' Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes ', British Journal of Cancer . https://doi.org/10.1038/s41416-018-0274-8Test
British Journal of Cancer

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b0161853805f94870acd38f5d6cbae5Test
https://www.pure.ed.ac.uk/ws/files/76353096/2018_Oct_CG_Candidate_biomarkers_of_PARP_inhibitor_sensitivity_in_ovarian_cancer_beyond_the_BRCA_genes.pdfTest

تنقيح النتائج